This site is intended for healthcare professionals

Genentech announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person.

Read time: 1 mins
Published:25th Nov 2020
Genentech, a member of the Roche Group announced that the FDA has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis. Post-exposure prophylaxis with single-dose Xofluza was evaluated in the Phase III BLOCKSTONE study, which was recently published in The New England Journal of Medicine. BLOCKSTONE evaluated Xofluza compared with placebo as a preventive treatment for household members (adults and children) who were living with someone with influenza. Xofluza showed a statistically significant prophylactic effect on influenza after a single oral dose in people exposed to an infected household contact. The proportion of household members 12 years of age and older who developed influenza was 1% in participants treated with Xofluza and 13% in the placebo-treated group. Xofluza was well tolerated in this study and no new safety signals were identified. See-"Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts".- Hideyuki Ikematsu, M.D., Frederick G. Hayden, M.D., Keiko Kawaguchi, M.S., Masahiro Kinoshita, M.Pharm.,et al. July 23, 2020. N Engl J Med 2020; 383:309-320 DOI: 10.1056/NEJMoa1915341.
Condition: Influenza
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.